Trizuljak Jakub, Srovnal Josef, Plevová Karla, Brychtová Yvona, Semerád Lukáš, Bakešová Denisa, Létalová Eva, Benedíková Andrea, Mayer Jiří, Hajdúch Marián, Pospíšilová Šárka, Doubek Michael
Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Czech Republic.
Institute of Molecular and Translational Medicine, Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University, and Faculty Hospital Olomouc, Czech Republic.
Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):439-42. doi: 10.1016/j.clml.2015.02.003. Epub 2015 Feb 11.
Merkel cell polyomavirus (MCPyV), a ubiquitous DNA tumor virus, has been found to be associated with Merkel cell carcinoma and chronic lymphocytic leukemia (CLL). Previous studies have reported conflicting results on the frequency and potential pathogenetic role of MCPyV in CLL. The aim of this study was to evaluate MCPyV's association with CLL and its prognostic significance.
Between 2006 and 2013, DNA samples obtained from CLL patients (n = 119) before treatment were tested for MCPyV using quantitative real-time polymerase chain reaction analysis and verified by gel electrophoresis. Only samples testing positive by both methods were considered valid.
We found that 13 (11%) of 119 CLL cases were positive for MCPyV. Between the groups of MCPyV-positive and -negative patients, there was no significant difference in the sex, age, cytogenetics, presence of p53 defect, or immunoglobulin heavy chain (IGHV) mutational status. In the subset of MCPyV-negative patients, advanced Rai stage (III to IV) was found more frequently, and therapy was initiated more often. There was no difference in overall response rate, median progression-free survival, and overall survival between both groups. We did not observe any new positivity after treatment in initially MCPyV-negative patients.
This study provides the first analysis of the prognostic role of MCPyV in CLL. MCPyV occurrence seems to be a relatively rare event during the course of CLL. MCPyV is also unlikely to influence the outcome of CLL patients.
默克尔细胞多瘤病毒（MCPyV）是一种普遍存在的DNA肿瘤病毒，已被发现与默克尔细胞癌和慢性淋巴细胞白血病（CLL）相关。先前的研究报告了MCPyV在CLL中的频率和潜在致病作用的相互矛盾的结果。本研究的目的是评估MCPyV与CLL的关联及其预后意义。
在2006年至2013年期间，使用定量实时聚合酶链反应分析对治疗前从CLL患者（n = 119）获得的DNA样本进行MCPyV检测，并通过凝胶电泳进行验证。只有两种方法检测均为阳性的样本才被视为有效。
我们发现119例CLL病例中有13例（11%）MCPyV呈阳性。在MCPyV阳性和阴性患者组之间，性别、年龄、细胞遗传学、p53缺陷的存在或免疫球蛋白重链（IGHV）突变状态均无显著差异。在MCPyV阴性患者亚组中，更频繁地发现晚期Rai分期（III至IV期），并且更频繁地开始治疗。两组之间的总缓解率、中位无进展生存期和总生存期无差异。我们在最初MCPyV阴性的患者治疗后未观察到任何新的阳性病例。
本研究首次分析了MCPyV在CLL中的预后作用。MCPyV的出现似乎是CLL病程中相对罕见的事件。MCPyV也不太可能影响CLL患者的预后。
